PD-L1 Expression in Mastocytosis

被引：6

作者：

Williams, Margaret ^{[1
,2
]}

Lidke, Diane S. ^{[3
,4
]}

Hartmann, Karin ^{[5
]}

George, Tracy I. ^{[1
,2
]}

机构：

[1] Univ Utah, Dept Pathol, Salt Lake City, UT 84112 USA

[2] ARUP Labs, Salt Lake City, UT 84108 USA

[3] Univ New Mexico, Dept Pathol, Albuquerque, NM 87102 USA

[4] Univ New Mexico, Comprehens Canc Ctr, Albuquerque, NM 87102 USA

[5] Univ Basel, Div Allergy, Dept Dermatol, CH-4031 Basel, Switzerland

来源：

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2019年 / 20卷 / 09期

关键词：

immune checkpoint; PD-1; PD-L1; mastocytosis;

D O I：

10.3390/ijms20092362

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Programmed death 1 (PD-1), when activated by its ligands PD-L1 and PD-L2, suppresses active immune cells in normal immune regulation to limit autoimmunity and, in tumors, as a mechanism of immune evasion. PD-L1 expression has been described as both a prognostic and predictive marker in many solid and hematologic neoplasms, as targeted therapies against the PD-1/PD-L1 interaction have gained clinical importance. PD-L1 expression has been assessed in a few studies on mastocytosis. We review this literature and the need for further investigation of the tumor-immune interaction in mastocytosis.

引用

页数：6

共 17 条

[1]

[Anonymous], 2019, NONSM CELL LUNG CANC

[2] Innate vs. Adaptive: PD-L1-mediated immune resistance by melanoma [J].

Berry, Sneha ;

Taube, Janis M. .

ONCOIMMUNOLOGY, 2015, 4 (10)

[3] Variability of PD-L1 expression in mastocytosis [J].

Hatch, Ellen W. ;

Geeze, Mary Beth ;

Martin, Cheyenne ;

Salama, Mohamed E. ;

Hartmann, Karin ;

Eisenwort, Gregor ;

Blatt, Katharina ;

Valent, Peter ;

Gotlib, Jason ;

Lee, Ji-Hyun ;

Chen, Lu ;

Ward, Heather H. ;

Lidke, Diane S. ;

George, Tracy I. .

BLOOD ADVANCES, 2018, 2 (03) :189-199

[4] Harmonization of PD-L1 testing in oncology: a Canadian pathology perspective [J].

Ionescu, D. N. ;

Downes, M. R. ;

Christofides, A. ;

Tsao, M. S. .

CURRENT ONCOLOGY, 2018, 25 (03) :E209-E216

[5] PD-1 Regulates the Growth of Human Mastocytosis Cells [J].

Kataoka, Tatsuki R. ;

Fujimoto, Masakazu ;

Moriyoshi, Koki ;

Koyanagi, Itsuko ;

Ueshima, Chiyuki ;

Kono, Fumihiko ;

Tsuruyama, Tatsuaki ;

Okayama, Yoshimichi ;

Ra, Chisei ;

Haga, Hironori .

ALLERGOLOGY INTERNATIONAL, 2013, 62 (01) :99-104

[6] Expression of PD-L1 in mastocytosis [J].

Kuklinski, Lawrence F. ;

Kim, Jinah .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) :1010-1012

[7] The Prognostic and Clinicopathological Roles of PD-L1 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis [J].

Li, Yan ;

He, Meizhi ;

Zhou, Yaoyao ;

Yang, Chen ;

Wei, Shuyi ;

Bian, Xiaohui ;

Christopher, Odong ;

Xie, Lang .

FRONTIERS IN PHARMACOLOGY, 2019, 10

[8]

National Comprehensive Cancer Network, 2019, HEP CANC VERS 2

[9] The prognostic and clinicopathological significance of PD-L1 expression in patients with diffuse large B-cell lymphoma: a meta-analysis [J].

Qiu, Liping ;

Zheng, Hanlu ;

Zhao, Xiaoying .

BMC CANCER, 2019, 19 (1)

[10] Expression of programmed cell death ligand-1 in mastocytosis correlates with disease severity [J].

Rabenhorst, Anja ;

Leja, Silke ;

Schwaab, Juliana ;

Gehring, Manuela ;

Foerster, Anja ;

Arock, Michel ;

Reiter, Andreas ;

Raap, Ulrike ;

Hartmann, Karin .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2016, 137 (01) :314-318

← 1 2 →